Cencora Realigns Organizational and Reporting Structure to Strengthen Specialty Services and Improve Business Visibility
Cencora, a global pharmaceutical solutions company, has announced changes to its corporate organizational and financial reporting structure as part of its efforts to strengthen business execution, improve operational focus and provide greater visibility into its strategic priorities. The realignment is designed to bring related specialty businesses under unified leadership while organizing the company’s remaining pharmaceutical distribution operations according to their respective customer needs. Through this updated structure, Cencora aims to strengthen its capabilities across pharmaceutical distribution, specialty services, healthcare provider support and pharmaceutical manufacturer solutions.
The organizational changes reflect the company’s strategic developments over the past two years, during which Cencora has made investments to strengthen its leadership in specialty services and improve the support it provides to customers and business partners. The company has focused on expanding its capabilities across the pharmaceutical supply chain while developing services that address the changing requirements of healthcare providers, pharmaceutical manufacturers and patients. The latest realignment is intended to build on these efforts by creating a more focused organizational structure that supports pharmaceutical innovation and the delivery of specialized healthcare solutions.
Robert P. Mauch, President and Chief Executive Officer of Cencora, explained that the company has taken significant steps over the past two years to advance its strategy through investments in specialty capabilities and customer services. He noted that bringing the organization’s businesses into a more clearly defined structure reflects Cencora’s commitment to strengthening its position as a leader in supporting pharmaceutical innovation. According to Mauch, the updated reporting structure will also provide shareholders with a clearer understanding of the company’s progress against its strategic priorities and how its different businesses contribute to sustainable, long-term value creation across the enterprise.
The realignment will bring Cencora’s specialty businesses together under the leadership of Richard Tremonte. These operations will be reported within the Specialty Pharmaceutical and Provider Services segment. The decision to consolidate the specialty businesses under one leader is intended to help the company better support specialty healthcare providers and pharmaceutical manufacturers while taking advantage of its end-to-end specialty solutions. The segment will combine several business activities, including specialty distribution, group purchasing organization services, specialty medical practice support, global specialty logistics, third-party logistics and pharmaceutical commercialization services.
Specialty Pharmaceutical and Provider Services Segment
The Specialty Pharmaceutical and Provider Services segment will bring together Cencora’s specialty-focused businesses under a unified organizational structure. This segment will cover services supporting specialty pharmaceutical distribution, healthcare provider operations, clinical research, pharmaceutical logistics and commercialization. By organizing these activities under one leader, the company intends to strengthen coordination across its specialty capabilities and provide more integrated support to its customers and partners. The structure is also intended to make the company’s specialty operations more visible to shareholders and other stakeholders.
One important component of the segment will be specialty distribution and group purchasing organization (GPO) services. These operations support access to pharmaceuticals and contracting arrangements for thousands of community-based specialists across the United States. Specialty physicians often require access to complex and high-value medications used in areas such as oncology and other specialized medical fields. Distribution and GPO services help support these practices by providing pharmaceutical access and related purchasing arrangements. Bringing these services together with the company’s other specialty capabilities is intended to strengthen the support available to specialty healthcare providers.
The segment will also include oncology and retina management services organization (MSO) platforms. These platforms provide administrative and operational support to physicians, helping specialty medical practices manage different aspects of their business activities. Their services include clinical trial support, research capabilities, and data and analytics services. These capabilities are important for specialty practices that participate in clinical research and need access to operational resources and information to support their activities. Through these platforms, Cencora supports physicians in managing practice requirements while participating in specialized healthcare and research environments.
Another important component will be global specialty logistics. These operations support the distribution and handling of clinical trial materials and complex therapies across international markets. Cencora’s global specialty logistics network includes 140 logistics sites across more than 50 countries. This infrastructure supports pharmaceutical companies and healthcare partners that require specialized logistics capabilities for products with complex handling and distribution requirements. Clinical trials and advanced therapies can involve multiple locations and specialized supply chain processes, making reliable logistics support an important part of pharmaceutical development and delivery.
The Specialty Pharmaceutical and Provider Services segment will also include multinational third-party logistics (3PL) operations. These services support pharmaceutical supply chain activities across North America and Europe. According to the company, the multinational 3PL business supports 23 million lines across 15 countries. These operations form part of the broader logistics capabilities that help pharmaceutical manufacturers manage product movement and distribution across different markets. Bringing these services into the specialty-focused organizational structure is intended to strengthen the coordination of Cencora’s international specialty logistics and supply chain offerings.
Commercialization services will represent another area within the segment. These services include hub-and-spoke solutions in Canada, along with global pharmacovigilance, regulatory affairs and market access capabilities. Hub-and-spoke solutions are designed to support pharmaceutical commercialization and related services across healthcare markets. Pharmacovigilance activities focus on monitoring and evaluating the safety of medicines, while regulatory affairs services support pharmaceutical companies in navigating regulatory requirements. Market access solutions help address the processes involved in making pharmaceutical products available to healthcare systems and patients. Together, these capabilities provide support to manufacturers across different stages of the pharmaceutical product lifecycle.
Pharmaceutical Distribution and Services Segment
Alongside the consolidation of specialty operations, Cencora will organize its remaining U.S. businesses and its smaller European wholesale pharmaceutical distribution business under the Pharmaceutical Distribution and Services segment. This structure will allow the company to continue leveraging its distribution scale and supply chain efficiencies while recognizing the different requirements of its customer groups. The company intends to organize its remaining U.S. operations into two primary business verticals: Health Systems and Retail Pharmacy and Alternate Care.
The revised structure is intended to provide clearer operational responsibilities and enable Cencora to focus on the specific needs of hospitals, health systems, government facilities, retail pharmacies and other healthcare providers. Pharmaceutical distribution plays an important role in ensuring that medicines move efficiently from manufacturers to healthcare organizations and ultimately reach patients. By organizing its operations around distinct customer categories, Cencora aims to maintain the benefits of its existing distribution network while strengthening the services available to each group.
Health Systems Business Led by Matthew Glucksmann
The Health Systems vertical will be led by Matthew Glucksmann. This business will focus on providing comprehensive pharmaceutical distribution and related solutions to leading hospitals, health systems and government facilities. These healthcare organizations require dependable access to pharmaceutical products, along with services that support the management of complex pharmacy operations. Cencora’s updated structure will bring together several capabilities designed to address these requirements, including integrated wholesale and specialty distribution, health system pharmacy support services and unit-dose repackaging.
An important element of the Health Systems vertical will be its integrated distribution model. This model combines wholesale and specialty distribution capabilities to support the pharmaceutical supply requirements of hospitals and healthcare systems. Healthcare organizations frequently manage a broad range of medications, including traditional pharmaceuticals and specialty products that may require additional handling and distribution considerations. An integrated approach is intended to help meet these different requirements through coordinated distribution services.
The vertical will also provide holistic health system pharmacy support services, including specialty GPO services. These offerings are intended to support healthcare organizations in managing their pharmacy operations and accessing pharmaceutical purchasing arrangements. Specialty GPO services can be particularly relevant to health systems that manage specialized treatments and require support for their pharmaceutical procurement activities. By bringing these capabilities together under Matthew Glucksmann’s leadership, Cencora aims to provide a more coordinated service structure for its hospital and health system customers.
Unit-dose repackaging will also remain part of the Health Systems business. This service involves packaging medications into individual doses to support medication management and distribution requirements within healthcare facilities. Unit-dose packaging can help hospitals and other institutions organize medication administration processes and support their pharmacy operations. Its inclusion within the Health Systems vertical reflects the range of services Cencora provides beyond traditional pharmaceutical wholesale distribution.
Retail Pharmacy and Alternate Care Business Led by Tim Cernohous
The Retail Pharmacy and Alternate Care vertical will be led by Tim Cernohous. This business will focus on serving pharmacies that play an important role in community healthcare and supporting patient access to pharmaceutical products. Retail pharmacies are an important part of the healthcare delivery system because they provide patients with access to prescription medications and related pharmacy services within their communities. Cencora’s pharmaceutical distribution operations support these organizations by helping ensure that medicines are available through established supply chain channels.
The Retail Pharmacy and Alternate Care vertical will focus on the requirements of pharmacies and other alternate care customers. These customers operate in different healthcare environments and depend on reliable pharmaceutical supply arrangements to support their daily operations. By establishing a dedicated leadership structure for this business, Cencora aims to maintain a clear focus on the needs of retail pharmacies and alternate care providers. The organization will continue to leverage its distribution scale and supply chain capabilities to support pharmaceutical access across these customer categories.
The appointment of Tim Cernohous to lead this vertical establishes a dedicated leadership responsibility for these operations within the Pharmaceutical Distribution and Services segment. The structure separates the customer focus of retail pharmacies and alternate care organizations from the hospital and health system operations led by Matthew Glucksmann. This division reflects Cencora’s approach of organizing its remaining U.S. businesses around the distinct requirements of different healthcare customer groups.
European Pharmaceutical Distribution Business
Cencora’s smaller European wholesale pharmaceutical distribution business will also be included within the Pharmaceutical Distribution and Services segment. This business will be led by Juan Guerra. The European operations form part of the company’s pharmaceutical distribution activities and support the movement of pharmaceutical products through wholesale distribution channels.
The inclusion of the European wholesale business within this segment provides a defined reporting structure for these operations alongside the company’s remaining U.S. pharmaceutical distribution businesses. The appointment of Juan Guerra as its leader establishes dedicated management responsibility for the European distribution activities. This arrangement also reflects the company’s decision to distinguish its specialty-focused international operations from its wholesale pharmaceutical distribution business.
While the Specialty Pharmaceutical and Provider Services segment will include global specialty logistics and multinational third-party logistics capabilities, the European wholesale pharmaceutical distribution business will remain within Pharmaceutical Distribution and Services. This distinction helps define the reporting responsibilities of the company’s different business activities according to their operational focus and customer requirements.
Updated Financial Reporting and Shareholder Visibility
In addition to announcing the organizational changes, Cencora stated that it is providing recast unaudited summary segment financial information for fiscal years 2025 and 2026. The company will make this information available through a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.
The recast financial information is intended to reflect the company’s updated segment reporting structure. As the specialty businesses and pharmaceutical distribution operations are reorganized, presenting historical financial information under the revised structure will help shareholders better understand the reporting changes. It will also provide investors with a basis for reviewing the company’s business performance according to the updated segment organization.
Financial reporting visibility is an important part of the realignment because investors need to understand how different business activities contribute to the company’s overall results. By providing recast information for fiscal 2025 and 2026, Cencora is making historical segment information available in a format aligned with its new reporting structure. The information will be unaudited, as specified by the company.
The revised reporting arrangement is also intended to provide shareholders with a clearer view of Cencora’s progress against its strategic priorities. As Robert P. Mauch explained, the company wants investors to better understand how its organizational structure supports its strategy and contributes to sustainable, long-term value creation.
Cencora’s Focus on Specialty Capabilities and Pharmaceutical Distribution
The latest organizational realignment reflects Cencora’s efforts to align its business structure with its strategic priorities and the changing requirements of the pharmaceutical industry. The company is bringing together specialty services that support pharmaceutical manufacturers, physicians, clinical research and complex therapy distribution while maintaining dedicated structures for wholesale pharmaceutical distribution. This approach is designed to improve leadership focus and strengthen the coordination of services across its operations.
The Specialty Pharmaceutical and Provider Services segment will combine a broad range of capabilities, from specialty distribution and physician support to international logistics and commercialization services. Meanwhile, the Pharmaceutical Distribution and Services segment will focus on the company’s remaining U.S. businesses and European wholesale pharmaceutical distribution operations. The two-segment structure reflects the different activities and customer requirements within Cencora’s business.
Through the leadership appointments of Richard Tremonte, Matthew Glucksmann, Tim Cernohous and Juan Guerra, the company has also established specific management responsibilities across its realigned operations. These appointments are part of the announced organizational structure and are intended to support the execution of the company’s business priorities.
Overall, Cencora’s updated organizational and reporting structure represents a strategic effort to strengthen its specialty leadership, maintain pharmaceutical distribution efficiencies and improve transparency for shareholders. By bringing related businesses together and providing recast historical segment information, the company aims to create a clearer view of its operations and strategic progress. The announcement focuses on organizational alignment and reporting visibility, building on investments made over the previous two years to enhance specialty capabilities and customer support across the pharmaceutical industry.
Source link: https://www.cencora.com/
